Gastric cancer complicated with hemophagocytic lymphohistiocytosis: case report and a brief review

Yu-Shi Zhou¹, Yan-Cheng Cui¹, Mu-Jun Yin¹, Qi-Wei Xie¹, Zhan-Long Shen¹, Hong-Xia Shi², Ying-Jiang Ye¹, Bin Liang¹

¹Department of Gastrointestinal Surgery, Peking University People's Hospital, Beijing, China; ²Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China

Abstract: Hemophagocytic lymphohistiocytosis (HLH) comprises a group of severe immune function disorders that can lead to immune-mediated organ damage. There are two subtypes of HLH: primary and secondary. Secondary HLH is associated with infectious, oncologic, chemotherapeutic, and other underlying causes, and studies on HLH triggered by tumors have mainly focused on hematological malignancies. Secondary HLH in patients with solid tumors is rare. Here, we present two cases of gastric cancer complicated with HLH. The patient 1 was diagnosed as gastric cancer at stage I and got intractable fever after a distal subtotal gastrectomy without any evidence of infections or other complications. The patient 2 suffered from unresectable gastric adenocarcinoma and got fever, hemorrhagic rashes, and petechiae in mouth after six cycles of neoadjuvant chemotherapy. After detailed and comprehensive examinations, HLH was diagnosed in the two patients according to 2004 HLH diagnostic criteria, and the patients received treatment including immunosuppressive agents immediately. After therapy, the two patients showed partial remission, but both eventually died due to HLH relapse or progression of the primary tumor. The treatment regimen for HLH is intricate, and only a few relevant studies have focused on the treatment of cancer patients with HLH. The high mortality associated with this disease calls for more attention and additional research to improve the prognosis for these patients.

Keywords: Hemophagocytic lymphohistiocytosis (HLH); gastric cancer; chemotherapy; case report

Introduction

Hemophagocytic lymphohistiocytosis (HLH) is a group of severe immune function disorders in which the body's immune system can damage the organs. There are two types of HLH: primary and secondary. Primary HLH mostly arises from inherited immune disorders, and secondary HLH is usually triggered by inflammation, malignant tumor, chemotherapy, hematopoietic stem cell transplantation, or infection (1).

Studies of malignant tumors complicated with HLH have mainly focused on hematological malignancies, including lymphoma and leukemia (2). We report two cases of gastric cancer complicated with HLH. To our knowledge, there are no relevant prior published studies of HLH triggered by gastric cancer. We present the following cases in accordance with the CARE reporting checklist (available at http://dx.doi.org/10.21037/jgo-20-432).

Case presentation

Case 1

A 68-year-old man was admitted to the Hepatology Department of Peking University People's Hospital with intermittent fever and anorexia lasting 2 months. The
Patient’s medical and family histories were unremarkable. Computed tomography (CT) and gastroscopy revealed a tumor at the antrum of the stomach, which biopsy confirmed to be high-grade intraepithelial neoplasia. Subsequently, the patient underwent distal subtotal gastrectomy (Figure 1A), and in the first week postoperatively, the patient did not complain of any major discomfort. Postoperative pathology confirmed gastric cancer, which was staged as pT1aN0M0 according to the 8th edition of the American Joint Committee on Cancer staging manual.

After 1 week, the patient developed an intractable fever with a maximum temperature of 39.1 °C. CT scans and blood tests showed no evidence of hepatitis, human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), syphilis, tuberculosis, bacterial infection, or other complications; however, enlargement of the spleen was indicated (Figure 1B). Therefore, positron emission tomography-computed tomography (PET-CT) was performed, and cancer recurrence or metastasis was excluded. Bone marrow biopsy indicated hemophagocytosis (Figure 1C). Furthermore, blood tests showed anemia, thrombocytopenia, hypoproteinemia, and a significant increase in the levels of ferritin and soluble CD25 (sCD25) (Table 1). Further, a flow cytometry test showed low natural killer (NK) cell activity. The patient was diagnosed with HLH and was transferred to a specialized hospital for further treatment. After two cycles of the DEP regimen (liposomal doxorubicin 20 mg, for 1 day; etoposide 100 mg, for 1 day; methylprednisolone 20 mg, twice daily for 3 days), the patient remained disease-free for 5 months but eventually died from HLH relapse.

Table 1 Cases and hemophagocytic lymphohistiocytosis (HLH) 2004 diagnostic criteria

<table>
<thead>
<tr>
<th>HLH 2004</th>
<th>Case 1</th>
<th>Case 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever 38.5 °C or more</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Cytopenia (affecting at least 2 of 3 cell lineages in peripheral blood)</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Hypertriglyceridemia and/or hypofibrinogenemia</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Hemophagocytosis in bone marrow or spleen or lymph nodes</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Low or absent NK cell activity</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ferritin ≥500 μg/L</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>sCD25 ≥2,400 U/mL</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

sCD25, soluble CD25.
Case 2

The second patient was a 54-year-old woman who had been diagnosed as having unresectable gastric adenocarcinoma with pyloric obstruction 5 months previously (Figure 2A). After six cycles of neoadjuvant chemotherapy (FOLFOX for two cycles and FOLFIRI for four cycles), the patient was admitted to Peking University People's Hospital due to an unexplained fever lasting 10 days. On admission, she was pale, with facial edema, and her body temperature fluctuated between 38–41.3 °C. Furthermore, she had progressive, scattered hemorrhagic rashes all over her body (Figure 2B), and petechiae in her mouth. Blood tests indicated anemia, hypothrombinemia, and hypofibrinogenemia, as well as a significant increase in the levels of ferritin and sCD25. Bone marrow biopsy indicated hemophagocytosis (Figure 2C). Laboratory tests showed no evidence of infection. Based on these findings, secondary HLH was confirmed, and chemotherapy based on etoposide (200 mg twice a week) together with dexamethasone (20 mg daily) was subsequently administered.

One week after beginning chemotherapy treatment, the patient’s body temperature returned to normal, and the subcutaneous hemorrhage and body rashes subsided. Blood tests showed an increase in fibrinogen and a decrease in ferritin levels, although pancytopenia was also observed. Considering that the HLH-triggered cytokine storm was under control and the chemotherapy had induced myelosuppression, etoposide administration was terminated after 3 treatments, and dexamethasone was tapered (10 mg daily for 1 week, then 5 mg daily). Two weeks after regimen adjustment, the patient’s fever, facial edema, and skin rash returned, indicating relapse of HLH. Because of their effects on inhibiting HLH and stimulating bone marrow, dexamethasone (20 mg daily) and cyclosporine (75 mg twice daily) were administered. Five days later, the patient’s condition stabilized. Considering the pancytopenia, cyclosporine (75 mg twice daily) was continuously administered, but chemotherapy, such as etoposide and docetaxel (salvage therapy for HLH) was no longer given. Moreover, the dose of dexamethasone was reduced (17.5 mg daily for 2 weeks, 15 mg daily for 2 weeks, followed by 12.5 mg daily). During this period, the patient’s condition was stable, and the pancytopenia and hyperferritinemia showed progressive decline.

Figure 2 Clinical information of case 2. (A) CT image showing gastric cancer and pyloric obstruction. (B) Scattered hemorrhagic rash on the lower limb. (C) Wright-Giemsa staining of bone marrow biopsy showing hemophagocytosis (original magnification: ×100). (D) CT image showing abdominal ascites and peritoneal metastasis. CT, computed tomography.
The patient remained in a stable condition for 8 weeks, but then ascites and bloody stools returned. CT showed a peritoneal metastasis lesion (Figure 2D). The patient underwent symptomatic therapy; however, the hypoproteinemia and electrolyte disturbance could not be corrected. She gradually progressed to renal failure and eventually died from multiple organ failure.

**Ethical statement**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient.

**Discussion**

Secondary HLH, also known as acquired HLH, is associated with infectious, oncologic, chemotherapeutic, and other underlying causes (1). Here, we reported two cases of gastric cancer complicated with HLH. The 2004 HLH diagnostic criteria and the results of the two patients are presented in Table 1.

**Epidemiology**

The available epidemiologic data on HLH are limited. HLH has an estimated annual incidence of 1 per 800,000 people in Japan (3) and less than 10 per 1 million children in Italy, Sweden, and the United States (4-6). Solid tumor-associated HLH is even rarer. For instance, in a study of 2,197 adults with HLH, only 1.46% of patients had HLH triggered by a solid tumor (7).

However, the incidence of HLH secondary to a solid tumor may be underestimated. Intractable fever is common in cancer patients, especially those who undergo chemotherapy. Early studies considered cancer to be the cause of fever in 15–20% of cases of fever of an unknown origin (8), and such cases were characterized as a neoplastic fever. However, HLH may be behind cases of neoplastic fever. Furthermore, the imbalance of immune homeostasis induced by chemotherapy and the underlying malignancy would lower the threshold for triggering HLH (2).

**Pathophysiology**

Based on the pathophysiology of primary HLH, defective granule-mediated cytotoxicity of cytotoxic T lymphocytes (CTLs) and NK cells is known to be the main cause of HLH (17). The inability of NK cells or CTLs to down-regulate the immune response results in a significant inflammatory response triggered by hypersecretion of cytokines, including interferon-γ, tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, and IL-12. This so-called cytokine storm could be pathogenically related to the development of HLH, thereby resulting in significant tissue damage and organ failure (7).

The exact underlying mechanism of HLH secondary to a solid tumor has yet to be elucidated. It is assumed that the hyperinflammation is triggered by the secretion of pro-inflammatory cytokines and persistent antigen stimulation by tumor cells. Further, the imbalance of immune homeostasis induced by chemotherapy and the underlying malignancy would lower the threshold for triggering HLH (2).

**Treatment and prognosis**

Neither the low incidence of solid tumor-associated HLH nor the lack of relevant related studies should exclude HLH from being considered in cancer patients, especially as early diagnosis and treatment are required due to the poor prognosis and high mortality. Both patients in the present study as well as five patients reported in the literature have died.

In the treatment of HLH, early diagnosis and intervention are crucial (1). The most common symptoms of HLH include intractable fever, erythema, and subcutaneous bleeding (25). When these symptoms are present in a cancer patient, especially those undergoing chemotherapy and immune checkpoint inhibitor therapy, screening tests including sCD25, ferritin, NK cell activity, and bone marrow biopsy need to be considered at an early stage in order to diagnose HLH as soon as possible.

Gastric cancer associated with HLH is challenging to cure. Treatment for solid tumor-associated HLH should take into account the primary tumor, patient status, organ...
<table>
<thead>
<tr>
<th>Author</th>
<th>Primary tumor</th>
<th>Gender/age</th>
<th>Possible triggers</th>
<th>Onset clinical features of HLH</th>
<th>Therapies</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jiwnani et al. [2012]</td>
<td>Squamous cell carcinoma of the lung</td>
<td>M/68 y</td>
<td>Malignancy</td>
<td>Fever, erythema</td>
<td>Steroids</td>
<td>Death</td>
</tr>
<tr>
<td>Declerck et al. [2012]</td>
<td>Metastatic prostate cancer</td>
<td>M/57 y</td>
<td>Malignancy</td>
<td>Abnormal clotting</td>
<td>Vincristine and docetaxel</td>
<td>Complete remission</td>
</tr>
<tr>
<td>Schwarz et al. [2013]</td>
<td>Three patients with colon cancer and two patients with pseudomyxoma peritonei</td>
<td>-</td>
<td>Malignancy, chemotherapy and infection</td>
<td>Thrombocytopenia</td>
<td>Anti-infection, reoperation, supportive treatment</td>
<td>Two patients died and three survived</td>
</tr>
<tr>
<td>Murphy et al. [2015]</td>
<td>Wilms tumor</td>
<td>F/4 y</td>
<td>Malignancy and chemotherapy</td>
<td>Fever, pancytopenia</td>
<td>Dexamethasone, etoposide, immunoglobulin and radical resection of metastatic Wilms tumor</td>
<td>Remained free of disease for 7 months from the end of therapy</td>
</tr>
<tr>
<td>Ciccarese et al. [2015]</td>
<td>Synovial Sarcoma</td>
<td>M/20 y</td>
<td>Malignancy and chemotherapy</td>
<td>Fever, pancytopenia</td>
<td>Dexamethasone and gamma globulin</td>
<td>Remission of symptoms</td>
</tr>
<tr>
<td>Nascimento et al. [2016]</td>
<td>Adrenal neuroblastoma</td>
<td>F/14 m</td>
<td>Malignancy and chemotherapy</td>
<td>Fever, pancytopenia</td>
<td>Chemotherapy with etoposide</td>
<td>Death</td>
</tr>
<tr>
<td>Stabler et al. [2017]</td>
<td>Metastatic malignant melanoma</td>
<td>F/47 y</td>
<td>Malignancy</td>
<td>Fever, asthenia, dyspnea, and thrombopenia</td>
<td>Etiologic treatment with etoposide</td>
<td>Death</td>
</tr>
<tr>
<td>Hantel et al. [2018]</td>
<td>Malignant melanoma</td>
<td>F/35 y</td>
<td>Malignancy and immunotherapy</td>
<td>Anemia, hyperferritinemia, and splenomegaly</td>
<td>Methylprednisolone</td>
<td>Complete remission</td>
</tr>
<tr>
<td>Sadaat and Jang [2018]</td>
<td>Metastatic malignant melanoma</td>
<td>M/58 y</td>
<td>Malignancy and immunotherapy</td>
<td>Fever</td>
<td>Prednisone</td>
<td>Complete remission</td>
</tr>
<tr>
<td>Sasaki et al. [2018]</td>
<td>Malignant melanoma</td>
<td>F/60 y</td>
<td>Malignancy and immunotherapy</td>
<td>Fever, hepatosplenomegaly, erythema, pancytopenia, and hyperferritinemia</td>
<td>Prednisolone</td>
<td>Partial remission</td>
</tr>
<tr>
<td>Wakefield et al. [2018]</td>
<td>Papillary thyroid carcinoma</td>
<td>M/19 y</td>
<td>Malignancy</td>
<td>Fever, pancytopenia, and splenomegaly</td>
<td>Dexamethasone and surgery of the primary tumor</td>
<td>Remained in remission</td>
</tr>
<tr>
<td>Okawa et al. [2019]</td>
<td>Non-small cell lung cancer</td>
<td>M/78 y</td>
<td>Malignancy and immunotherapy</td>
<td>Fever, splenomegaly</td>
<td>Steroid pulse therapy with antibiotics</td>
<td>Complete remission</td>
</tr>
<tr>
<td>Al-Samkari et al. [2019]</td>
<td>Metastatic breast cancer</td>
<td>F/58 y</td>
<td>Malignancy and immunotherapy</td>
<td>Fever, erythema, and anemia</td>
<td>Methylprednisolone</td>
<td>Complete remission</td>
</tr>
<tr>
<td>Lorenz et al. [2019]</td>
<td>Prostate cancer</td>
<td>M/68 y</td>
<td>Malignancy and immunotherapy</td>
<td>Fever, splenomegaly, pancytopenia, and hyperferritinemia</td>
<td>Steroids, ciclosporin A and etoposide</td>
<td>Complete remission</td>
</tr>
</tbody>
</table>

Table 2 (continued)
Table 2 (continued)

<table>
<thead>
<tr>
<th>Author</th>
<th>Primary tumor</th>
<th>Gender/age</th>
<th>Possible triggers</th>
<th>Onset clinical features of HLH</th>
<th>Therapies</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akagi et al. [2020] (23)</td>
<td>Lung adenocarcinoma</td>
<td>M/74 y</td>
<td>Malignancy and immunotherapy</td>
<td>Fever, pancytopenia, and erythema</td>
<td>Dexamethasone, etoposide, and antibiotics</td>
<td>Complete remission</td>
</tr>
<tr>
<td>Mizuta et al. [2020] (24)</td>
<td>Malignant melanoma</td>
<td>F/69 y</td>
<td>Malignancy and immunotherapy</td>
<td>Fever</td>
<td>Prednisolone</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

HLH, hemophagocytic lymphohistiocytosis; y, year; m, month.

Figure 3 Time course of body temperature (red line) and ferritin level (gray line) of case 2. Under the abscissa, the immunosuppressive therapy regimes are shown. Blue, red, and black arrows indicate the timing of HLH diagnosis, HLH relapse, and gastric cancer progression. HLH, hemophagocytic lymphohistiocytosis.

function, and anti-neoplastic therapies (25). There is a lack of relevant trials to guide the treatment of cancer patients with HLH. The immunosuppressive agents used in the treatment of HLH mainly include glucocorticoids, cyclophosphamide, cyclosporine, etoposide and doxorubicin (26,27). Among these agents, glucocorticoids are as always the initial treatment and are used in most regimens, and others drugs are from the 1994 and 2004 HLH protocols, or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) and DEP (doxorubicin, etoposide, and methylprednisolone) regimens. CHOP is mostly used for lymphoma-associated HLH, and DEP is used as a salvage therapy (27). As in case 2, we applied a regimen including etoposide and dexamethasone, which was mainly based on the 2004 HLH protocol (25). Etoposide eliminates activated immune cells to calm the cytokine storm (28), but its long-term usage may cause bone marrow suppression. Moreover, etoposide also serves as palliative chemotherapy for advanced gastric cancer, and has been found beneficial for curing both HLH and cancer. The main challenge is assessing the fine balance between the potential benefits of suppressing inflammatory cytokines and the detrimental effect of myelosuppression.

If possible, resection of the primary tumor is a treatment option, although it does not eliminate HLH relapse (as seen in case 1). In our experience, once HLH relapsed, the poor status of the patient imposes great restrictions on treatment, thus increasing the risk of death. Therefore, properly extending immunosuppressive therapy could reduce the risk of HLH recurrence, even though the primary tumor may progress without resection and cause death (as seen in case 2).

Monitoring the treatment effect is crucial. In case 2, we monitored the fever curve, ferritin and sCD25 levels, liver function tests, and fibrinogen to determine the treatment response. Our data showed that the ferritin levels were correlated with disease activity (Figure 3), which matched...
the experience of other authors (29).

Solid tumor-associated HLH has a low incidence but high mortality. In this report, we showed that secondary HLH is associated with gastric cancer, not only during the late stage, but also at an early stage. Therefore, more attention and additional research are needed to bring benefits to patients with solid tumors complicated with HLH.

**Conclusions**

Although solid tumor-associated HLH is rare, it is still a concern. Recognizing the typical symptoms in patients undergoing chemotherapy and immune checkpoint inhibitor therapy could significantly accelerate early diagnosis and help determine a treatment regimen. The prognosis of patients with uncontrolled primary disease is extremely poor. Therefore, more attention should be paid to solid tumor-associated HLH to improve the prognosis of patients.

**Acknowledgments**

The authors would like to thank the families of the patients for allowing us to share the details of their cases.

**Funding:** None.

**Footnote**

**Reporting Checklist:** The authors have completed the CARE reporting checklist. Available at [http://dx.doi.org/10.21037/jgo-20-432](http://dx.doi.org/10.21037/jgo-20-432)

**Peer Review File:** Available at [http://dx.doi.org/10.21037/jgo-20-432](http://dx.doi.org/10.21037/jgo-20-432)

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at [http://dx.doi.org/10.21037/jgo-20-432](http://dx.doi.org/10.21037/jgo-20-432)). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient.


Cite this article as: Zhou YS, Cui YC, Yin MJ, Xie QW, Shen ZL, Shi HX, Ye YJ, Liang B. Gastric cancer complicated with hemophagocytic lymphohistiocytosis: case report and a brief review. J Gastrointest Oncol 2021;12(2):892-899. doi: 10.21037/jgo-20-432